ADMA Biologics Inc. (ADMA)
NASDAQ: ADMA · IEX Real-Time Price · USD
2.37
+0.14 (6.28%)
At close: Aug 12, 2022 4:00 PM
2.45
+0.08 (3.38%)
After-hours:
Aug 12, 2022 7:59 PM EDT
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
|
80.94 | 42.22 | 29.35 | 16.99 | 22.76 | 10.66 | 7.18 | 5.92 | 3.07 | 1.12 | Upgrade
|
| Revenue Growth (YoY)
|
91.72% | 43.85% | 72.79% | -25.37% | 113.49% | 48.53% | 21.34% | 92.84% | 174.35% | 46.92% | Upgrade
|
| Cost of Revenue
|
79.77 | 61.29 | 39.5 | 42.19 | 29.16 | 6.36 | 4.31 | 3.74 | 2.02 | 0.67 | Upgrade
|
| Gross Profit
|
1.17 | -19.07 | -10.16 | -25.21 | -6.4 | 4.3 | 2.87 | 2.17 | 1.04 | 0.45 | Upgrade
|
| Selling, General & Admin
|
42.9 | 35.05 | 25.91 | 22.5 | 18.75 | 8.49 | 6.75 | 4.82 | 4.37 | 3.14 | Upgrade
|
| Research & Development
|
3.65 | 5.91 | 2.34 | 3.93 | 5.57 | 7.69 | 7.02 | 9.52 | 9.3 | 3.47 | Upgrade
|
| Other Operating Expenses
|
13 | 4.89 | 3.01 | 8.65 | 8.58 | 5.45 | 4.62 | 3.85 | 2.42 | 1.75 | Upgrade
|
| Operating Expenses
|
59.55 | 45.84 | 31.27 | 35.08 | 32.91 | 21.63 | 18.38 | 18.19 | 16.09 | 8.36 | Upgrade
|
| Operating Income
|
-58.37 | -64.91 | -41.42 | -60.29 | -39.31 | -17.33 | -15.51 | -16.02 | -15.04 | -7.91 | Upgrade
|
| Interest Expense / Income
|
13.06 | 11.99 | 8.99 | 5.52 | 3.29 | 2.24 | 1.84 | 1.29 | 0.62 | 0.03 | Upgrade
|
| Other Expense / Income
|
0.22 | -1.15 | -2.14 | -0.07 | 1.16 | -0.05 | 0.61 | 0.06 | -0.13 | -0.02 | Upgrade
|
| Pretax Income
|
-71.65 | -75.75 | -48.28 | -65.74 | -43.76 | -19.52 | -17.97 | -17.36 | -15.53 | -7.92 | Upgrade
|
| Income Tax
|
0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.55 | 0 | -0.62 | Upgrade
|
| Net Income
|
-71.65 | -75.75 | -48.28 | -65.74 | -43.76 | -19.52 | -17.97 | -16.81 | -15.53 | -7.3 | Upgrade
|
| Net Income Common
|
-71.65 | -75.75 | -48.28 | -65.74 | -43.76 | -19.52 | -17.97 | -16.81 | -15.53 | -7.3 | Upgrade
|
| Shares Outstanding (Basic)
|
140 | 86 | 54 | 45 | 23 | 12 | 10 | 9 | 7 | 5 | Upgrade
|
| Shares Outstanding (Diluted)
|
140 | 86 | 54 | 45 | 23 | 12 | 10 | 9 | 7 | 5 | Upgrade
|
| Shares Change
|
62.03% | 58.51% | 20.27% | 97.37% | 88.39% | 16.72% | 12.06% | 42.27% | 24.03% | 1391.31% | Upgrade
|
| EPS (Basic)
|
-0.51 | -0.88 | -0.89 | -1.45 | -1.91 | -1.61 | -1.73 | -1.81 | -2.38 | -1.39 | Upgrade
|
| EPS (Diluted)
|
-0.51 | -0.88 | -0.89 | -1.45 | -1.91 | -1.61 | -1.73 | -1.81 | -2.38 | -1.39 | Upgrade
|
| Free Cash Flow Per Share
|
-0.90 | -1.33 | -1.47 | -1.43 | -1.75 | -1.51 | -1.48 | -1.83 | -1.70 | -1.33 | Upgrade
|
| Gross Margin
|
1.40% | -45.20% | -34.60% | -148.40% | -28.10% | 40.30% | 39.90% | 36.70% | 34.00% | 40.20% | Upgrade
|
| Operating Margin
|
-72.10% | -153.80% | -141.10% | -354.90% | -172.70% | -162.60% | -216.10% | -270.80% | -490.40% | -707.40% | Upgrade
|
| Profit Margin
|
-88.50% | -179.40% | -164.50% | -387.10% | -192.30% | -183.10% | -250.40% | -284.20% | -506.20% | -653.00% | Upgrade
|
| Free Cash Flow Margin
|
-155.50% | -271.70% | -272.60% | -381.40% | -175.50% | -172.10% | -215.20% | -287.90% | -361.30% | -628.10% | Upgrade
|
| Effective Tax Rate
|
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.18% | 0.00% | 7.80% | Upgrade
|
| EBITDA
|
-53.1 | -59.82 | -36.03 | -56.77 | -37.78 | -16.81 | -15.66 | -15.83 | -14.7 | -7.71 | Upgrade
|
| EBITDA Margin
|
-65.60% | -141.70% | -122.80% | -334.30% | -166.00% | -157.60% | -218.10% | -267.60% | -479.20% | -689.20% | Upgrade
|
| Depreciation & Amortization
|
5.5 | 3.94 | 3.26 | 3.45 | 2.69 | 0.47 | 0.47 | 0.25 | 0.21 | 0.18 | Upgrade
|
| EBIT
|
-58.59 | -63.76 | -39.29 | -60.22 | -40.47 | -17.28 | -16.13 | -16.08 | -14.91 | -7.89 | Upgrade
|
| EBIT Margin
|
-72.40% | -151.00% | -133.90% | -354.50% | -177.80% | -162.00% | -224.70% | -271.80% | -486.00% | -705.50% | Upgrade
|
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).